Ignite Creation Date:
2025-12-17 @ 5:08 PM
Ignite Modification Date:
2025-12-24 @ 6:08 AM
Study NCT ID:
NCT00745433
Status:
COMPLETED
Last Update Posted:
2023-11-02
First Post:
2008-09-01
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide
Sponsor:
Novo Nordisk A/S
Organization:
Study Overview
Official Title:
REPAMET 2: Observational Study of the Switch From Metformin Monotherapy to Bitherapy With Metformin and Repaglinide
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REPAMET 2
Brief Summary:
This study is conducted in Europe. The aim of this observational study is to investigate the efficacy (e.g. glycemic control) and safety (e.g. hypoglycemic episodes) when adding repaglinide to a monotherapy of metformin in type 2 diabetic patients under normal clinical practice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: